Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs

This study has been completed.
Information provided by:
Ionis Pharmaceuticals, Inc. Identifier:
First received: June 16, 2003
Last updated: October 15, 2007
Last verified: October 2007
The purposes of this Phase 1/2 study are to examine the safety, tolerability, and antiviral activity of ISIS 14803, when given in combination with peginterferon alfa and ribavirin, to patients who either failed to have at least a 100-fold HCV reduction at Week 12 of standard therapy or still have detectable HCV at Week 24.

Condition Intervention Phase
Hepatitis C, Chronic
Drug: ISIS 14803, peginterferon alfa, ribavirin
Phase 1
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Ionis Pharmaceuticals, Inc.:

Estimated Enrollment: 22
Study Start Date: May 2004
Detailed Description:

Previously untreated chronic hepatitis C patients undergoing therapy with peginterferon alfa and ribavirin have a very poor probability of achieving a sustained virologic response if they either do not have a 100-fold or greater reduction in their plasma HCV RNA levels at the 12th week of treatment or have detectable plasma HCV RNA at the 24th week of treatment. ISIS 14803 is an experimental antiviral medication for the treatment of chronic hepatitis C that has been given to chronic hepatitis C patients in two previous single-agent clinical trials (approximately 70 patients).

In this clinical research study, 12 weeks of ISIS 14803 treatment will be added to the peginterferon alfa and ribavirin treatment regimen of previously untreated chronic hepatitis C patients who have a very poor probability of achieving a sustained virologic response based upon either of the above two criteria. Enrolled patients must continue to be treated with peginterferon alfa and ribavirin and must begin ISIS 14803 treatment within four weeks of their HCV RNA result report date. ISIS 14803 will be given as a two-hour intravenous infusion, two times each week, for 12 weeks. Depending on their HCV response to the three-drug combination, patients may continue treatment with peginterferon alfa and ribavirin after the end of ISIS 14803 treatment. Patients will be monitored for at least eight weeks (for safety) after the end of ISIS 14803 treatment and possibly for longer (for sustained virologic response). Two dose levels of ISIS 14803 will be studied in this trial, 3 and 6 mg/kg ideal body weight.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria (partial list):

  • Age 18 to 65 years.
  • Infection with HCV.
  • Prior liver biopsy indicating chronic hepatitis.
  • Received at least 12 weeks of continuous peginterferon alfa and ribavirin therapy.
  • HCV infection was untreated prior to current peginterferon alfa and ribavirin regimen.
  • Either less than 100-fold reduction in plasma or serum HCV RNA despite receiving 12 weeks of peginterferon alfa and ribavirin therapy or detectable HCV RNA at week 24 of therapy.
  • Prothrombin time and aPTT within normal reference range.
  • Serum bilirubin concentration within normal reference range.
  • Give written informed consent to participate in the study.

Exclusion criteria (partial list):

  • Pregnant women or nursing mothers or women of childbearing potential without adequate contraception.
  • Systemic corticosteroid therapy within 3 months of screening.
  • Serum ALT greater than 5 x upper limit of normal range.
  • HIV or HBV infection.
  • Decompensated liver disease.
  • Evidence of cirrhosis.
  • Severe depression with suicidal ideation requiring hospitalization within one year of screening.
  • Any disease condition associated with active bleeding or requiring anticoagulation with heparin or warfarin.
  • Any condition which, in the opinion of the Investigator, would preclude participation in or interfere with compliance.
  • Alcohol or drug abuse.
  • Is undergoing or has undergone treatment with another investigational drug, biologic agent or device within 30 days of screening
  • History of cryoglobulinemia or vasculitis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00062816

  Show 25 Study Locations
Sponsors and Collaborators
Ionis Pharmaceuticals, Inc.
  More Information

Additional Information: Identifier: NCT00062816     History of Changes
Other Study ID Numbers: ISIS 14803-CS3
Study First Received: June 16, 2003
Last Updated: October 15, 2007

Keywords provided by Ionis Pharmaceuticals, Inc.:

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Hepatitis, Chronic
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents processed this record on April 26, 2017